The fact
This progress comes six months ahead of schedule, boosting investor expectations.
The stock could see a medium-term revaluation in the biotech sector.
This progress comes six months ahead of schedule, boosting investor expectations.
The stock could see a medium-term revaluation in the biotech sector.